Totale

Adaptive Neuromodulation GmbH (ANM) is a German medical technology research company that was founded in December 2005 as a spin-off from the Jülich Research Centre (Forschungszentrum Jülich). ANM is tightly integrated in the scientific network of the Jülich Research Centre and Cologne University; both institutions enjoy outstanding scientific reputations and are world leaders in the field of neuromodulation.

ANM develops treatment methods for patients with neurological conditions such as Parkinson's disease, pain or tinnitus on the basis of a patented neuro-technological innovation in the field of neuromodulation – known as Coordinated Reset (CR®) – that was established during more than ten years of systematic scientific work carried out at the Research Centre Jülich.

Milestones in ANM's still-young corporate history include the European registration from February 2010 in conjunction with the CE mark and TÜV certification, followed by the market launch of the acoustic T30 CR® neurostimulator for the treatment of chronic tinnitus.

Future scientific highlights:

  • Since November 2011: Start of a 12-months Real Life Tinnitus Study with 200 patients in 20 German study centres.
  • Q1 2012: Start of a multicentre, randomized, double-blinded, placebo-controlled clinical long-term tinnitus study enrolling approx. 100 patients in Great Britain.

 


tuevlogo tt_accreditation_25_klein IP10_Plakette_nom_web_klein

Last Updated ( Friday, 27 January 2012 12:23 )